Advertisement

Topics

Medgenics to Present Clinical Data at the 20th Congress of the European Hematology Association

20:00 EDT 3 Jun 2015 | Globe Newswire

- New Data Presented from Ongoing Phase 1/2 Study of TARGTEPOTM

PHILADELPHIA, June 4, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that clinical data from the ongoing Phase 1/2 study of the Company's TARGTEPOTM (Transduced Autologous Restorative Gene Therapy) system in end stage renal disease will be presented at the 20th Congress of the European Hematology Association (EHA) taking place June 11-14, 2015 in Vienna, Austria.

The data will be presented by Dr. Shany Blum, Vice President of Medical Affairs, during a poster session. Details are as follows:

  • Date & Time: Saturday, June 13, 2015 at 5:15 p.m. CEST
  • Title: A Prospective Clinical Trial of Prolonged Autologous Erythropoietin (EPO) Secretion from TARGTEPO In EPO-Dependent End Stage Renal Disease Patients Showed EPO Independence for Over 8 Months
  • Session: Gene Therapy, Cellular Immunotherapy and Vaccination
  • Abstract: P723
  • Location: Poster area (Hall C)

Presentation materials will be available in the Investor Relations portion of the company's website following conclusion of the session.

About Medgenics, Inc.

Medgenics is developing the TARGT (Transduced Autologous Restorative Gene Therapy) system, a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides using ex vivo gene therapy and the patient's own tissue for the treatment of orphan and rare diseases. For more information, visit the Company's website at www.medgenics.com

Forward-looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.

CONTACT: Medgenics, Inc.
         John Leaman
         john.leaman@medgenics.com
         
         Brian Piper
         Brian.piper@medgenics.com
         
         Stern Investor Relations
         Beth DelGiacco
         212-362-1200
         Beth@sternir.com

Medgenics, Inc. logo

NEXT ARTICLE

More From BioPortfolio on "Medgenics to Present Clinical Data at the 20th Congress of the European Hematology Association"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...